A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up
Year: 2022
Type: article
Source: Blood
Authors: Eytan Stein, Sheng F Cai, Ying Huang, Andrew Dunbar, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti A. Patel, Matthew C. Foster, Michael M. Boyiadzis, Robert H. Collins, Jordan Chervin, Abigail B. Shoben, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Timothy Chen, Ashley O. Yocum, Franchesca Druggan, Sonja Marcus, Mona Stefanos, Molly Martycz, Brian J. Druker, Alice S. Mims, Uma Borate, Amy Burd, John C. Byrd, Ross L. Levine
Institutions: Memorial Sloan Kettering Cancer Center, The Ohio State University, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Chicago, University of Utah, Huntsman Cancer Institute, Winship Cancer Institute, University of California, Los Angeles, University of California, San Francisco, Mayo Clinic in Florida, Mayo Clinic, University of Kansas, The University of Texas Southwestern Medical Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, UPMC Hillman Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Foundation Medicine (United States), Blood Cancer United, Oregon Health & Science University, University of Cincinnati
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310161849